Found: 31
Select item for more details and to access through your institution.
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2009, v. 64, n. 2, p. 398
- By:
- Publication type:
- Article
CARISEL Çalışmasının Bir Etkililik ve Güvenlilik Alt Grup Analizi.
- Published in:
- Mediterranean Journal of Infection, Microbes & Antimicrobials, 2024, v. 13, p. 105
- By:
- Publication type:
- Article
DTG/3TC Sabit Doz Kombinasyonu (SDK), TAF Bazlı Rejim (TBR) ile Eş Etkilidir: 96-hafta TANGO Alt-grup Analizleri.
- Published in:
- Mediterranean Journal of Infection, Microbes & Antimicrobials, 2021, p. 93
- By:
- Publication type:
- Article
Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis.
- Published in:
- Open Forum Infectious Diseases, 2024, v. 11, n. 7, p. 1, doi. 10.1093/ofid/ofae365
- By:
- Publication type:
- Article
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study
- Published in:
- Open Forum Infectious Diseases, 2024, v. 11, n. 5, p. 1, doi. 10.1093/ofid/ofae227
- By:
- Publication type:
- Article
Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO Study.
- Published in:
- Open Forum Infectious Diseases, 2024, v. 11, n. 1, p. 1, doi. 10.1093/ofid/ofad626
- By:
- Publication type:
- Article
Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide–Based Regimens.
- Published in:
- Open Forum Infectious Diseases, 2023, v. 10, n. 7, p. 1, doi. 10.1093/ofid/ofad359
- By:
- Publication type:
- Article
Implementation of long‐acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations.
- Published in:
- Journal of the International AIDS Society, 2024, v. 27, n. 7, p. 1, doi. 10.1002/jia2.26243
- By:
- Publication type:
- Article
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies.
- Published in:
- AIDS Research & Therapy, 2024, v. 21, n. 1, p. 1, doi. 10.1186/s12981-024-00604-9
- By:
- Publication type:
- Article
Impact of Human Immunodeficiency Virus Type 1 Subtypes on Virologic Response and Emergence of Drug Resistance among Children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial.
- Published in:
- Journal of Infectious Diseases, 2002, v. 186, n. 5, p. 617
- By:
- Publication type:
- Article
Intrapartum Mucosal Exposure to Human Immunodeficiency Virus Type 1 (HIV-1) of Infants Born to HIV-1-Infected Mothers Correlates with Maternal Plasma Virus Burden.
- Published in:
- Journal of Infectious Diseases, 1998, v. 177, n. 4, p. 1097
- By:
- Publication type:
- Article
Measurement of Human Herpesvirus 7 Load in Peripheral Blood and Saliva of Healthy Subjects by Quantitative Polymerase Chain Reaction.
- Published in:
- Journal of Infectious Diseases, 1996, v. 174, n. 2, p. 396, doi. 10.1093/infdis/174.2.396
- By:
- Publication type:
- Article
SEGURANÇA E EFICÁCIA DA TERAPIA ANTIRRETROVIRAL BASEADA EM DOLUTEGRAVIR, NA SEMANA 48, EM ADULTOS COINFECTADOS HIV/TB.
- Published in:
- Brazilian Journal of Infectious Diseases, 2018, v. 22, p. 14, doi. 10.1016/j.bjid.2018.10.027
- By:
- Publication type:
- Article
Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study.
- Published in:
- Journal of Infectious Diseases, 2014, v. 210, n. 3, p. 354, doi. 10.1093/infdis/jiu051
- By:
- Publication type:
- Article
Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study.
- Published in:
- Journal of Infectious Diseases, 2013, v. 207, n. 5, p. 740
- By:
- Publication type:
- Article
Human herpesviruses 6 and 7 as potential pathogens after liver transplant: Prospective comparison with the effect of cytomegalovirus.
- Published in:
- Journal of Medical Virology, 1999, v. 59, n. 4, p. 496, doi. 10.1002/(SICI)1096-9071(199912)59:4<496::AID-JMV12>3.0.CO;2-U
- By:
- Publication type:
- Article
Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy.
- Published in:
- Journal of Medical Virology, 1999, v. 59, n. 3, p. 364, doi. 10.1002/(SICI)1096-9071(199911)59:3<364::AID-JMV17>3.0.CO;2-V
- By:
- Publication type:
- Article
Sequence variation within the human immunodeficiency virus V3 loop at seroconversion.
- Published in:
- Journal of Medical Virology, 1993, v. 41, n. 4, p. 270, doi. 10.1002/jmv.1890410403
- By:
- Publication type:
- Article
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144.
- Published in:
- Viruses (1999-4915), 2023, v. 15, n. 6, p. 1350, doi. 10.3390/v15061350
- By:
- Publication type:
- Article
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study
- Published in:
- Clinical Infectious Diseases, 2020, v. 71, n. 8, p. 1920, doi. 10.1093/cid/ciz1243
- By:
- Publication type:
- Article
Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial.
- Published in:
- Clinical Infectious Diseases, 2020, v. 70, n. 4, p. 549, doi. 10.1093/cid/ciz256
- By:
- Publication type:
- Article
Integrated Population Exposure–Response of Dolutegravir in HIV‐1 Supports Bridging of Clinical Response Influenced by Relevant Intrinsic and Extrinsic Patient Characteristics.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 116, n. 4, p. 1100, doi. 10.1002/cpt.3370
- By:
- Publication type:
- Article
Changes in Inflammatory Biomarkers and Baseline Variables After Switching to Dolutegravir/Lamivudine(DTG/3TC) in 2 Randomized Clinical Trials of Virologically Suppressed Adults: 48-Week Pooled Analysis.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. 272
- By:
- Publication type:
- Article
Efficacy and Safety of Switching to Dolutegravir/ Lamivudine by Baseline Regimen in Virologically Suppressed Adults: 48-Week Pooled Analysis.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. 271
- By:
- Publication type:
- Article
Efficacy and Safety of Switching to Dolutegravir/ Lamivudine (DTG/3TC) in Treatment-Experienced, Virologically Suppressed PLHIV Aged ≥50 Years: Pooled Results From the TANGO and SALSA Studies.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. 273
- By:
- Publication type:
- Article
Impact of treatment adherence on efficacy of DTG + 3TC and DTG + TDF/FTC: pooled week 144 analysis of the GEMINI-1 and GEMINI-2 clinical studies.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. S302
- By:
- Publication type:
- Article
Week 48 metabolic health after switch to DTG/3TC vs CAR by baseline regimen (SALSA).
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. S300
- By:
- Publication type:
- Article
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial
- Published in:
- Clinical Infectious Diseases, 2022, v. 75, n. 6, p. 975, doi. 10.1093/cid/ciac036
- By:
- Publication type:
- Article
Population Pharmacokinetic Analysis of Dolutegravir in Treatment‐Experienced Adults Living with HIV‐1.
- Published in:
- Journal of Clinical Pharmacology, 2024, v. 64, n. 11, p. 1407, doi. 10.1002/jcph.2494
- By:
- Publication type:
- Article
New concepts in AIDS pathogenesis. Ed. by Montagnier and Gougeon, Marcel Dekker Inc, New York (1993). pp. 334. ISBN 0-8247-9127-4.
- Published in:
- Reviews in Medical Virology, 1994, v. 4, n. 3, p. 223, doi. 10.1002/rmv.1980040310
- By:
- Publication type:
- Article
Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study.
- Published in:
- Journal of the International Association of Providers of AIDS Care, 2024, p. 1, doi. 10.1177/23259582241269837
- By:
- Publication type:
- Article